Mark J. Ratain to Leukemia
This is a "connection" page, showing publications Mark J. Ratain has written about Leukemia.
Connection Strength
0.877
-
Troxacitabine in patients with refractory leukemia. J Clin Oncol. 2002 Aug 01; 20(15):3356; author reply 3356-7.
Score: 0.184
-
Negative innovation: when patents are bad for patients. Nat Biotechnol. 2021 08; 39(8):914-916.
Score: 0.171
-
Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). J Natl Cancer Inst. 2015 Oct; 107(10).
Score: 0.112
-
Pharmacodynamics and long-term toxicity of etoposide. Cancer Chemother Pharmacol. 1994; 34 Suppl:S64-8.
Score: 0.101
-
New perspectives on the toxicity of etoposide. Semin Oncol. 1992 Dec; 19(6 Suppl 13):78-83.
Score: 0.094
-
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8.
Score: 0.068
-
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987 Nov; 70(5):1412-7.
Score: 0.066
-
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3612s-6s.
Score: 0.060
-
Correspondence re: Xiu F. Hu et al., Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res., 50: 2953-2957, 1990. Cancer Res. 1991 Mar 15; 51(6):1749-50.
Score: 0.021